Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivavotinib (TAK-659) in Relapsed or Refractory AML
NCT02323113Phase 2Terminated
- Sponsor
- Calithera Biosciences
- Start
- Mar 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mivavotinib in acute myeloid leukemia (AML), sponsored by Calithera Biosciences. Started Mar 2015; status: terminated.
02
Drugs
mivavotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02323113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323113.